Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
8.36
+0.18 (2.20%)
Apr 17, 2025, 4:00 PM EDT - Market closed

Maze Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22
Market Capitalization
368---
Enterprise Value
198---
Debt / Equity Ratio
0.140.144.940.32
Debt / EBITDA Ratio
0.400.40--
Debt / FCF Ratio
0.360.36--
Asset Turnover
1.071.07--
Quick Ratio
9.529.521.794.81
Current Ratio
9.769.762.095.11
Return on Equity (ROE)
50.48%50.48%-180.12%-
Return on Assets (ROA)
23.07%23.07%-55.63%-
Return on Capital (ROIC)
25.42%25.42%-63.77%-
Return on Capital Employed (ROCE)
26.20%26.20%--
Buyback Yield / Dilution
-1933.20%-19.33%-13.82%-
Updated Jan 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q